Acasti to host conference call on tuesday, january 10, 2023 to discuss results from recent phase 1 pk studies for gtx-101 and gtx-102 that met all outcome measures

Laval, quÉbec, jan. 05, 2023 (globe newswire) -- acasti pharma inc. (“acasti” or the “company”) (nasdaq: acst and tsx-v: acst), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on tuesday, january 10, 2023 at 4:30 p.m. et to review the recently reported preliminary topline results from two separate phase 1 pharmacokinetic (pk) studies for gtx-101 and gtx-102. both studies successfully met all target outcome measures.
ACST Ratings Summary
ACST Quant Ranking